Immunotherapy’s cancer remit widens

In Nature this week; ‘Combination therapies hold great promise, but at what cost?‘ Andrew Baum, the London-based head of global health-care research at the investment bank Citi, forecasts that in ten years the drugs will be treating 60% of cancers and earning US$35 billion a year. CEO Immunovo Dr Joost van Bree: ‘Immunotherapy in oncology opens new promising pathways however it may also put our reimbursement systems under increasing pressure. The alternative of using therapeutic vaccine which require only minute amounts of antigen to reach comparable therapeutic effects will most likely be the next step in this development. We at Immunovo are committed to realizing that promising potential!